Compound News and Research

RSS

Will we ever eat pigs genetically engineered to give us healthy fats?

Researchers in the U.S. have created pigs that produce omega-3 fatty acids, which are believed to improve heart function and help reduce the risks for heart disease.

26 Mar 2006

PR Pharmaceuticals issued U.S. patent covering 2-methoxyestradiol for the treatment of diabetes

The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).

21 Mar 2006

Study to Rituximab's potential to preserve insulin production in newly diagnosed type 1 diabetics

A drug used to treat lymphoma, rheumatoid arthritis and other immune disorders may enable newly-diagnosed type 1 diabetics to save some of their pancreas function and thereby reduce their susceptibility to long-term complications.

20 Mar 2006

EntreMed announces new U.S. Patent - "Estrogenic Compounds as Anti-Mitotic Agents"

EntreMed has announced the issuance of U.S. Patent No. 7,012,070 covering methods of treatment for a broad range of indications with its lead clinical-stage compound, 2-methoxyestradiol (2ME2).

17 Mar 2006

Study explains how brain cells die in patients with Alzheimer's Disease

Researchers at Children's Hospital & Research Center at Oakland (CHRCO) have published a new study that is the first to explain how brain cells die in patients with Alzheimer's Disease.

15 Mar 2006

Man-made chemical compound targets and kills tumor cells

A man-made chemical compound called ARC causes tumor cells to die but leaves normal cells unharmed, researchers at the University of Illinois at Chicago report in a study highlighted in the March 15 issue of Cancer Research.

15 Mar 2006

Researchers synthesize nisin in a test tube

Scientists have made nisin, a natural antibiotic used for more than 40 years to preserve food, in a test tube for the first time using nature's toolbox.

13 Mar 2006

University of Michigan researchers target stubborn gram-negative bacteria

Ronald Woodard's team set out looking for a way to kill a stubborn type of bacteria and they succeeded - but not in the way he expected.

9 Mar 2006

Researchers find compound that interferes with the pathogenic effects of Huntington's disease

There is no cure for Huntington's, a neurodegenerative disorder that now afflicts 30,000 Americans, with another 150,000 at risk. The fatal disease, which is genetically inherited, usually strikes in midlife and causes uncontrolled movements, loss of cognitive function and emotional disturbance.

9 Mar 2006

Repligen commences phase 2 trial of RG2417 for bipolar depression

Repligen Corporation today announced that the Company has initiated a Phase 2 clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

9 Mar 2006

Novel compound may help fight obesity

A new study reveals an attractive new target for therapies aimed at the treatment of obesity and related metabolic disorders, researchers report in the March Cell Metabolism.

9 Mar 2006

Tibotec Pharmaceuticals receives NDA for investigational HIV protease inhibitor

Tibotec Pharmaceuticals has announced that the New Drug Application (NDA) for TMC114, an investigational HIV protease inhibitor, has been accepted for priority review by the United States Food and Drug Administration (FDA).

7 Mar 2006

Potential new treatment for Huntington and Parkinson patients

A potential new treatment for neurodegenerative disorders, which seems to be able to reduce the toxic protein aggregates characteristic of many of these diseases, is published online this week in the journal Proceedings of the National Academy of Sciences.

7 Mar 2006